• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Osmotic Tubulopathy in a Patient With COVID-19 Treated With Remdesivir.

作者信息

Wongboonsin Janewit, Shah Sujal I, Marty Francisco M, Mount David B, Rennke Helmut G, Murakami Naoka

机构信息

Renal Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.

出版信息

Kidney Int Rep. 2021 Jul;6(7):1987-1991. doi: 10.1016/j.ekir.2021.04.032. Epub 2021 May 12.

DOI:10.1016/j.ekir.2021.04.032
PMID:33997535
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8112887/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4729/8258575/5da210ae5bc2/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4729/8258575/5da210ae5bc2/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4729/8258575/5da210ae5bc2/gr1.jpg

相似文献

1
Osmotic Tubulopathy in a Patient With COVID-19 Treated With Remdesivir.一名接受瑞德西韦治疗的新冠肺炎患者出现渗透性肾小管病。
Kidney Int Rep. 2021 Jul;6(7):1987-1991. doi: 10.1016/j.ekir.2021.04.032. Epub 2021 May 12.
2
Remdesivir Treatment for COVID 19 in Pregnant Patients with Moderate to Severe Symptoms: Serial Case Report.瑞德西韦治疗中度至重度症状的COVID-19孕妇：系列病例报告
Infect Dis Rep. 2021 May 17;13(2):437-443. doi: 10.3390/idr13020042.
3
Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment.瑞德西韦治疗 COVID-19：系统的获益-风险评估。
Drug Saf. 2020 Jul;43(7):645-656. doi: 10.1007/s40264-020-00952-1.
4
Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient.采用液相色谱-串联质谱法对血浆瑞德西韦及其代谢物 GS-441524 进行定量分析。在一名新冠肺炎治疗患者中的应用。
Clin Chem Lab Med. 2020 Jun 22;58(9):1461-1468. doi: 10.1515/cclm-2020-0612. Print 2020 Aug 27.
5
Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis.瑞德西韦对COVID-19的死亡率益处：一项系统评价和荟萃分析。
Front Med (Lausanne). 2021 Jan 27;7:606429. doi: 10.3389/fmed.2020.606429. eCollection 2020.
6
Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019.瑞德西韦治疗 2019 年冠状病毒引起的肝脏疾病。
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2835-2836. doi: 10.1016/j.cgh.2020.07.050. Epub 2020 Jul 25.
7
Developing an Ethics Framework for Allocating Remdesivir in the COVID-19 Pandemic.制定伦理框架以在 COVID-19 大流行期间分配瑞德西韦。
Mayo Clin Proc. 2020 Sep;95(9):1946-1954. doi: 10.1016/j.mayocp.2020.06.016. Epub 2020 Jun 20.
8
Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.瑞德西韦治疗 COVID-19：肺部和静脉联合给药可能提供额外益处。
AAPS J. 2020 May 26;22(4):77. doi: 10.1208/s12248-020-00459-8.
9
The journey of remdesivir: from Ebola to COVID-19.瑞德西韦的历程：从埃博拉到新冠病毒。
Drugs Context. 2020 May 22;9. doi: 10.7573/dic.2020-4-14. eCollection 2020.
10
The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report.2019新型冠状病毒感染的危重症产科患者成功应用恢复期血浆疗法和瑞德西韦治疗：一例病例报告
Case Rep Womens Health. 2020 May 16;27:e00221. doi: 10.1016/j.crwh.2020.e00221. eCollection 2020 Jul.

引用本文的文献

1
Kidney damage associated with COVID-19: from the acute to the chronic phase.与 COVID-19 相关的肾脏损伤：从急性期到慢性期。
Ren Fail. 2024 Dec;46(1):2316885. doi: 10.1080/0886022X.2024.2316885. Epub 2024 Apr 1.
2
Collapsing focal segmental glomerulosclerosis secondary to COVID-19: A systematic review and meta-analysis.新型冠状病毒肺炎继发的塌陷性局灶节段性肾小球硬化：一项系统评价和荟萃分析
Ann Med Surg (Lond). 2023 Feb 7;85(2):92-101. doi: 10.1097/MS9.0000000000000107. eCollection 2023 Feb.
3
Osmotic Tubulopathy and Acute Thrombotic Microangiopathy in a Kidney Transplant Recipient With a Breakthrough SARS-CoV-2 Infection.

本文引用的文献

1
Remdesivir Use in the Setting of Severe Renal Impairment: A Theoretical Concern or Real Risk?瑞德西韦在严重肾功能损害患者中的应用：理论上的担忧还是真实的风险？
Clin Infect Dis. 2021 Dec 6;73(11):e3990-e3995. doi: 10.1093/cid/ciaa1851.
2
Kidney Biopsy Findings in Patients with COVID-19.COVID-19 患者的肾脏活检结果。
J Am Soc Nephrol. 2020 Sep;31(9):1959-1968. doi: 10.1681/ASN.2020060802. Epub 2020 Jul 17.
3
Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy.
一名肾移植受者发生突破性严重急性呼吸综合征冠状病毒2感染后出现渗透性肾小管病和急性血栓性微血管病
Kidney Med. 2022 Jul;4(7):100492. doi: 10.1016/j.xkme.2022.100492. Epub 2022 May 26.
4
A Propensity Score-Matched Observational Study of Remdesivir in Patients with COVID-19 and Severe Kidney Disease.瑞德西韦治疗 COVID-19 合并严重肾脏疾病患者的倾向评分匹配观察性研究。
Kidney360. 2021 Dec 3;3(2):269-278. doi: 10.34067/KID.0006152021. eCollection 2022 Feb 24.
接受持续肾脏替代治疗的重症患者中磺丁基醚-β-环糊精（SBECD）蓄积及伏立康唑药代动力学的评估。
Crit Care. 2015 Feb 3;19(1):32. doi: 10.1186/s13054-015-0753-8.
4
Evaluation of intravenous voriconazole in patients with compromised renal function.评估肾功能受损患者的静脉用伏立康唑。
BMC Infect Dis. 2013 Jan 16;13:14. doi: 10.1186/1471-2334-13-14.
5
Administration of voriconazole in patients with renal dysfunction.肾功能障碍患者伏立康唑的给药。
Clin Infect Dis. 2012 Apr;54(7):913-21. doi: 10.1093/cid/cir969. Epub 2012 Jan 19.
6
Pharmacokinetics of sulfobutylether-β-cyclodextrin (SBECD) in subjects on hemodialysis.血液透析患者中磺丁基醚-β-环糊精（SBECD）的药代动力学。
Nephrol Dial Transplant. 2012 Mar;27(3):1207-12. doi: 10.1093/ndt/gfr472. Epub 2011 Aug 24.
7
Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD).磺丁基醚-β-环糊精（SBECD）的基础和临床药理学评价。
J Pharm Sci. 2010 Aug;99(8):3291-301. doi: 10.1002/jps.22109.
8
Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes.渗透性肾病：因给予外源性溶质导致近端肾小管溶酶体蓄积的急性肾损伤。
Am J Kidney Dis. 2008 Mar;51(3):491-503. doi: 10.1053/j.ajkd.2007.10.044.
9
Cyclodextrin nephrosis in the rat.大鼠中的环糊精肾病
Am J Pathol. 1976 May;83(2):367-82.